In regard to tuberculosis (TB) and other major global epidemics, the use of new diagnostic tests is increasing dramatically, including in resource-limited countries. Although there has never been as much digital information generated, this data source has not been exploited to its full potential. In this opinion paper, we discuss lessons learned from the global scale-up of these laboratory devices and the pathway to tapping the potential of laboratory-generated information in the field of TB by using connectivity. Responding to the demand for connectivity, innovative third-party players have proposed solutions that have been widely adopted by field users of the Xpert MTB/RIF assay. The experience associated with the utilisation of these sys...
Molecular technology to identify relatedness between Mycobacterium tuberculosis complex isolates, re...
Tuberculosis (TB) remains a major global health problem. The World Health Organization (WHO) has set...
The global roll-out of Xpert MTB/RIF (Cepheid Inc., Sunnyvale, CA, USA) has changed the diagnostic l...
In regard to tuberculosis (TB) and other major global epidemics, the use of new diagnostic tests is ...
In regard to tuberculosis (TB) and other major global epidemics, the use of new diagnostic tests is ...
In regard to tuberculosis (TB) and other major global epidemics, the use of new diagnostic tests is ...
BACKGROUND:To reach WHO End tuberculosis (TB) targets, countries need a quality-assured laboratory n...
Early detection and effective treatment are crucial for tuberculosis control, but global case detect...
SummaryEarly detection and effective treatment are crucial for tuberculosis control, but global case...
The World Health Organization's 2035 vision is to reduce tuberculosis (TB) associated mortality by 9...
AbstractTo control tuberculosis (TB), it is necessary to detect the disease and provide effective tr...
BackgroundTo eliminate preventable deaths, disease and suffering due to tuberculosis (TB), improved ...
Tuberculosis (TB) remains a leading cause of morbidity and mortality worldwide with an estimated 9.0...
Nucleic acid amplification tests such as Xpert MTB/RIF (Xpert) have the potential to revolutionize t...
Global tuberculosis control has been riding a wave of progress over the past decade. Mortality and i...
Molecular technology to identify relatedness between Mycobacterium tuberculosis complex isolates, re...
Tuberculosis (TB) remains a major global health problem. The World Health Organization (WHO) has set...
The global roll-out of Xpert MTB/RIF (Cepheid Inc., Sunnyvale, CA, USA) has changed the diagnostic l...
In regard to tuberculosis (TB) and other major global epidemics, the use of new diagnostic tests is ...
In regard to tuberculosis (TB) and other major global epidemics, the use of new diagnostic tests is ...
In regard to tuberculosis (TB) and other major global epidemics, the use of new diagnostic tests is ...
BACKGROUND:To reach WHO End tuberculosis (TB) targets, countries need a quality-assured laboratory n...
Early detection and effective treatment are crucial for tuberculosis control, but global case detect...
SummaryEarly detection and effective treatment are crucial for tuberculosis control, but global case...
The World Health Organization's 2035 vision is to reduce tuberculosis (TB) associated mortality by 9...
AbstractTo control tuberculosis (TB), it is necessary to detect the disease and provide effective tr...
BackgroundTo eliminate preventable deaths, disease and suffering due to tuberculosis (TB), improved ...
Tuberculosis (TB) remains a leading cause of morbidity and mortality worldwide with an estimated 9.0...
Nucleic acid amplification tests such as Xpert MTB/RIF (Xpert) have the potential to revolutionize t...
Global tuberculosis control has been riding a wave of progress over the past decade. Mortality and i...
Molecular technology to identify relatedness between Mycobacterium tuberculosis complex isolates, re...
Tuberculosis (TB) remains a major global health problem. The World Health Organization (WHO) has set...
The global roll-out of Xpert MTB/RIF (Cepheid Inc., Sunnyvale, CA, USA) has changed the diagnostic l...